<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16667">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951209</url>
  </required_header>
  <id_info>
    <org_study_id>CX 000981-01</org_study_id>
    <nct_id>NCT01951209</nct_id>
  </id_info>
  <brief_title>Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis</brief_title>
  <official_title>PROSPECTIVE PILOT STUDY OF THE EFFECT OF RIFAXIMIN ON B-CELL DYSREGULATION IN CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David E. Kaplan, MD MSc</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veterans Health Administration CSR&amp;D Merit Review Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philadelphia VA Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States
      veterans. Cirrhosis is associated with impaired antibody responses and increased risk of
      bacterial infections. We have recently identified that cirrhosis is associated with
      abnormalities of memory B-cells, cells that make antibodies and help protect against
      bacterial infections. We have identified that chemicals associated with gut bacteria might
      play a role in causing these B-cell abnormalities. It is well known that gut bacteria have
      increased access to the blood in individuals with cirrhosis, a process called bacterial
      translocation.  We hypothesize that reducing bacteria counts in the gut by using
      poorly-absorbed antibiotics (also known as selective gut decontamination) will partially
      reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in CD27+ B-cell frequency</measure>
    <time_frame>Week 0 (Baseline) to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in basal B-cell activation</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>5 x 104/well B-cells negatively selected from normal donor PBMC will be cultured in 50% RPMI 1640/50% cirrhotic patient serum for 48 hours.  After 48 hours, B-cells will be assessed for activation markers such as HLA-DR geometric mean fluorescence intensity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in circulating markers of bacterial translocation</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma samples will be studied for sCD14 by ELISA, bacterial DNA by rtPCR of 16S ribosomal RNA using established techniques, and Limulus Amebocyte Lysate Assay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550mg orally twice daily for 12 weeks</description>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
    <arm_group_label>Placebo/Rifaximin</arm_group_label>
    <other_name>Rifaximin (Xifaxan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
    <arm_group_label>Placebo/Rifaximin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Hepatitis C infection as documented by detectable HCV RNA

          -  Child-Turcotte-Pugh stage A5-B8. Cirrhosis diagnosis may be based on either
             histological criteria (an previous liver biopsy showing F4/4 or F5-6/6 fibrosis) or
             clinical criteria (nodular liver on abdominal imaging, splenomegaly,
             thrombocytopenia, spider telangiectasias, palmar erythema, ascites, varices).

          -  Platelet count &lt; 150,000/ul

          -  Subject capable of giving informed consent

        Exclusion Criteria:

          -  Active alcohol use &gt; 20g/d

          -  Current or planned (within following 6 months) antiviral therapy for hepatitis C

          -  HIV co-infection

          -  Diagnosis of overt hepatic encephalopathy

          -  Current lactulose use

          -  Exposure to rifaximin, rifampin or rifabutin within 12 months

          -  History of C. difficile colitis

          -  History of adverse drug reaction or sensitivity to rifaximin, rifampin or rifabutin
             or any inactive components of rifaximin

          -  Pregnancy

          -  Anemia with hemoglobin &lt; 10g/dl or hematocrit &lt; 30%

          -  Chronic kidney disease with creatinine &gt; 2.1mg/dl

          -  Total bilirubin &gt; 3.0g/dl

          -  Active non-hepatic medical conditions such as congestive heart failure, chronic lung
             disease requiring oxygen, coronary artery disease with unstable angina

          -  Requirement for chronic immunosuppressive therapy such as corticosteroids,
             cyclophosphamide, azathioprine, TNF-alpha antagonists

          -  Chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid
             arthritis

          -  Post-liver transplantation status or anticipated liver transplantation within 6
             months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Kaplan, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David E Kaplan, MD MSc</last_name>
    <phone>215-823-5800</phone>
    <phone_ext>6729</phone_ext>
    <email>david.kaplan2@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David E Kaplan, MD MSc</last_name>
      <phone>215-823-5800</phone>
      <phone_ext>6729</phone_ext>
      <email>david.kaplan2@va.gov</email>
    </contact>
    <investigator>
      <last_name>David E Kaplan, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology. 2012 Mar;55(3):709-19. doi: 10.1002/hep.24689. Epub 2012 Jan 19.</citation>
    <PMID>21932384</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>October 18, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Philadelphia VA Medical Center</investigator_affiliation>
    <investigator_full_name>David E. Kaplan, MD MSc</investigator_full_name>
    <investigator_title>GI Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Human</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>B-cell</keyword>
  <keyword>Rifaximin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
